)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Relmada Therapeutics
Relmada Therapeutics (RLMD) investor relations material
Relmada Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary12 May, 2026
Executive summary
Reported robust 12-month Phase 2 data for NDV-01 in NMIBC, showing high complete response rates and durable efficacy, especially in BCG-unresponsive patients, with no progression to muscle-invasive disease or need for radical cystectomy.
Completed $160 million private placement/PIPE financing, strengthening the balance sheet and providing funding runway through 2029, including phase III RESCUE program completion.
Filed a provisional U.S. patent for NDV-01 in April 2026, potentially extending exclusivity to 2047 and enabling global filings.
Preparing to initiate phase III RESCUE program for NDV-01 and a proof-of-concept/Phase 2b study for sepranolone in Prader-Willi syndrome, both targeted for mid-2026.
Terminated esmethadone and psilocybin programs in 2025 after strategic review.
Financial highlights
Ended Q1 2026 with $234 million in cash, cash equivalents, and short-term investments, up from $93 million at year-end 2025, reflecting $150 million in net proceeds from March private financing.
Net loss for Q1 2026 was $19.1 million ($0.22 per share), compared to $17.6 million ($0.58 per share) in Q1 2025.
Research and development expense decreased to $8.1 million from $12 million year-over-year, mainly due to non-recurrent prior year costs and program terminations.
General and administrative expense rose to $11.4 million from $6.3 million year-over-year, mainly due to higher compensation and consulting costs.
Net cash used in operating activities was $15.1 million, down from $18.1 million in Q1 2025.
Outlook and guidance
On track to initiate phase III RESCUE program for NDV-01 and sepranolone Phase 2b study in Prader-Willi syndrome in mid-2026, with initial three-month NDV-01 Phase 3 data expected by year-end 2026.
Current cash resources expected to fund operations through 2029, including completion of key clinical programs.
Key milestones in 2026 include NDV-01 IND filing, Phase 3 trial initiations, and sepranolone Phase 2b start.
NDV-01 Phase III RESCUE enrollment timelines
Commercial impact of 2047 patent extension
NDV-01 efficacy vs approved BCG-unresponsive drugs
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Relmada Therapeutics
- NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials.RLMD
Corporate presentation12 May 2026 - NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead.RLMDCompany presentation12 May 2026
- NDV-01 delivers strong efficacy and safety in bladder cancer, with pivotal trials and funding secured.RLMDLeerink Global Healthcare Conference 202630 Apr 2026
- A strategic pivot and successful financing in 2025 set the stage for renewed growth and shareholder value.RLMDProxy filing17 Apr 2026
- Key votes include director elections, equity plan expansion, and increasing authorized shares.RLMDProxy filing17 Apr 2026
- Shareholders will vote on key governance, compensation, and capital structure changes after a pivotal turnaround.RLMDProxy filing6 Apr 2026
- Biotech pivots pipeline, raises $160M, and registers 33.7M shares for investor resale.RLMDRegistration filing3 Apr 2026
- NDV-01 demonstrates high efficacy in NMIBC; Phase 3 trials and strong cash position support growth.RLMDCorporate presentation1 Apr 2026
- NDV-01 phase II shows 76% 12-month CR and $160M financing supports phase III launch.RLMDQ4 202520 Mar 2026
Next Relmada Therapeutics earnings date
Q2 20266 Aug, 2026
Relmada Therapeutics
Next Relmada Therapeutics earnings date
Q2 20266 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage